- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00487214
Internet-based, Naturalistic Evaluation of Tolerability and Individual Patient Target Pressures With Bimatoprost 0.03% in Glaucoma
May 31, 2011 updated by: Allergan
The purpose of this study is to evaluate the range of target IOPs set for glaucoma patients starting monotherapy with bimatoprost and to evaluate patient and physician satisfaction with bimatoprost in "real-world" settings
Study Overview
Status
Completed
Conditions
Study Type
Observational
Enrollment (Actual)
361
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Sampling Method
Non-Probability Sample
Study Population
Patients with either open-angle glaucoma or ocular hypertension at 41 centers in the United States
Description
Inclusion Criteria:
- Patients with either open-angle glaucoma or ocular hypertension were eligible if they needed bilateral IOP reduction beyond what was achieved with their current medication, or if they were intolerant of other IOP-lowering medications.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Medical Affairs, Allergan
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
June 1, 2002
Primary Completion (Actual)
February 1, 2003
Study Completion (Actual)
February 1, 2003
Study Registration Dates
First Submitted
June 13, 2007
First Submitted That Met QC Criteria
June 14, 2007
First Posted (Estimate)
June 15, 2007
Study Record Updates
Last Update Posted (Estimate)
June 1, 2011
Last Update Submitted That Met QC Criteria
May 31, 2011
Last Verified
May 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- MEDNET2001
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Glaucoma, Open-Angle
-
AllerganRecruiting18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA) (ARGOS)Ocular Hypertension | Open-angle GlaucomaUnited States
-
Aerie PharmaceuticalsCompletedOcular Hypertension | Open-angle Glaucoma
-
West Virginia UniversityUniversity of Pittsburgh; University of MichiganWithdrawnOpen-angle Glaucoma
-
Glaukos CorporationUnknownOpen-Angle GlaucomaSpain, Germany, Austria, Turkey
-
Alcon ResearchWithdrawnOpen-Angle Glaucoma
-
Asociación para Evitar la Ceguera en MéxicoUnknown
-
Pharmaceutical Research NetworkCompleted
-
National Eye Institute (NEI)CompletedOpen-Angle Glaucoma